ライフサイエンスコーパス: tumor-infiltrating

1 -associated metastatic cervical cancer after tumor-infiltrating adoptive T cell therapy.

2 DSC subpopulations with different degrees of tumor-infiltrating and anti-inflammatory capabilities.

3 Interestingly, tumor-infiltrating and tumor-draining lymph node NK cell

4 GAC patients and shows that circulating and tumor-infiltrating ARG1-expressing cells were mainly imm

5 Comprehensive pancancer analyses of tumor-infiltrating B cell-receptor repertoires identifie

6 Our analysis reveals versatile functions of tumor-infiltrating B cells and their potential clinical

7 Tumor-infiltrating B cells are an important component in

8 Tumor-infiltrating B cells are heterogeneous, and their

9 uce the growth factor FGF-2, which activates tumor-infiltrating B cells to produce the growth factor

10 cluded elevated immunoglobulin expression by tumor-infiltrating B cells, NF-kappaB activation, and in

11 The presence of tumor-infiltrating B lymphocytes has been linked to a fa

12 on the surface of bacteria was used to track tumor-infiltrating bacteria by bioluminescence imaging u

13 ultiple tumor types on both cancer cells and tumor-infiltrating blood vessels, making it a potentiall

14 entiated tumor cell areas, tumor stroma, and tumor-infiltrating blood vessels.

15 pproach to anti-CTLA4 blockade that depletes tumor-infiltrating, but not tissue-resident, Tregs, pres

16 FNgamma and the proliferation marker Ki67 in tumor-infiltrating CAR T cells when combined with alpha-

17 Tumor-infiltrating CCR5(+) MDSCs displayed higher immuno

18 CX3CL1 did not correlate with the density of tumor-infiltrating CD3(+) T cells or CD68(+) macrophages

19 en CXCL2 or MIF expression and the number of tumor-infiltrating CD33(+) MDSCs (P<0.01).

20 s tumor rejection, associated with increased tumor-infiltrating CD4 and CD8 T cells.

21 PD-1 and CTLA-4 were upregulated on tumor-infiltrating CD4(+) and CD8(+) T cells in irradiat

22 Tumor-infiltrating CD4(+) and CD8(+) T cells in patients

23 observed in C3aR-deficient mice and returned tumor-infiltrating CD4(+) T cells to control levels.

24 ) cell depletion promoted GzmB expression by tumor-infiltrating CD4(+), and this was prevented by int

25 ng synergy was mediated by a small subset of tumor-infiltrating CD4+ T cells that express the high-af

26 There was no increase in tumor infiltrating CD8+ T cells expressing "exhaustion"

27 tokines occurs prior to increased numbers of tumor-infiltrating CD8 T cells and tumor regression in c

28 rognosis often correlates with the number of tumor-infiltrating CD8 T cells, but many of these cells

29 e activation and effector genes expressed by tumor-infiltrating CD8(+) and CD4(+) T cells, and tumor-

30 s also significantly increased the number of tumor-infiltrating CD8(+) T and natural killer cells, sl

31 Mettl14-deficient tumors increased cytotoxic tumor-infiltrating CD8(+) T cells and elevated secretion

32 hrough suppression of cytokine production by tumor-infiltrating CD8(+) T cells and potentially additi

33 croenvironment, increasing the proportion of tumor-infiltrating CD8(+) T cells and sensitizing tumors

34 ociated with PD-L1 suppression, increases in tumor-infiltrating CD8(+) T cells and tumor cell killing

35 The percentage of tumor-infiltrating CD8(+) T cells coexpressing PD-1 and

36 cells increase fat uptake with HFD, whereas tumor-infiltrating CD8(+) T cells do not.

37 Here we describe a subset of tumor-infiltrating CD8(+) T cells marked by high express

38 Tumor-infiltrating CD8(+) T cells with high CD39 express

39 Chop expression is increased in tumor-infiltrating CD8(+) T cells, which correlates with

40 stimulates the expansion and cytotoxicity of tumor-infiltrating CD8+ T cells and inhibits inflammator

41 Tumor-infiltrating CD8+ T cells mediate antitumor immune

42 he relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to ant

43 Tumor-infiltrating CD8-positive (CD8+) T lymphocytes pla

44 hoid, myeloid, mesenchymal) and abundance of tumor infiltrating cells.

45 ters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB.

46 nts were associated with profound changes in tumor-infiltrating cells compared with that in allo-BMT

47 oach represents a novel means for protecting tumor-infiltrating cells from tumor-associated oxidative

48 Analysis of tumor-infiltrating cells in dual PARP-1/PARP-2-deficienc

49 hoid, myeloid, mesenchymal) and abundance of tumor-infiltrating cells.

50 ere we define the 'molecular fingerprint' of tumor-infiltrating CTLs and identify potentially new tar

51 We performed transcriptomic profiling of tumor-infiltrating CTLs from treatment-naive patients wi

52 s immunotherapeutic regimen caused homing of tumor-infiltrating DC to draining lymph nodes and increa

53 oma (PDA), we show that a distinct subset of tumor-infiltrating dendritic cells (DC) promotes PDA gro

54 f the organisms revealed that the numbers of tumor-infiltrating dendritic cells (TIDC) drastically de

55 ors, including tumor-associated macrophages, tumor-infiltrating dendritic cells and regulatory T cell

56 on, transfecting a substantial proportion of tumor-infiltrating dendritic cells, macrophages, and T c

57 ALK5(DeltaCD8) mice have more tumor-infiltrating effector CD8(+) T cells, with more cy

58 model, a DNA hypomethylating drug increases tumor-infiltrating effector T cells, increases a subset

59 dominantly induces the expansion of specific tumor-infiltrating exhausted-like CD8 T cell subsets.

60 erexpressed in TMEs and induces apoptosis in tumor-infiltrating, Fas receptor-positive lymphocytes.

61 + breast cancers demonstrated high levels of tumor-infiltrating FOXP3+ cells (38%; range, 35%-41%).

62 reast cancer, we reinforced the concept that tumor-infiltrating gammadeltaT17 cells are endowed with

63 and may therefore affect the composition of tumor-infiltrating hematopoietic cells and subsequent tu

64 orating ("rebooting") pre-existing exhausted tumor-infiltrating ilymphocytes (TILs).

65 ion was evaluated by immunohistochemistry in tumor infiltrating immune cells, while PD-L1 expression

66 sive analysis and visualization functions of tumor infiltrating immune cells.

67 tive analysis of genomic, transcriptomic and tumor-infiltrating immune cell profiles demonstrated ali

68 he transcriptional landscape across multiple tumor-infiltrating immune cell types.

69 PD-L1 expression on tumor cells (TC) and tumor-infiltrating immune cells (IC), abundance of tumor

70 We develop a computational approach to study tumor-infiltrating immune cells and their interactions w

71 Tumor-infiltrating immune cells comprise a previously un

72 elerated tumor onset and increased levels of tumor-infiltrating immune cells comprised of CD11b(+) ce

73 We characterize tumor-infiltrating immune cells from transplant and prim

74 C, we examined steroid hormone receptors and tumor-infiltrating immune cells in metastatic lesions wi

75 When studying nutrient usage of tumor-infiltrating immune cells in mice, we detected a s

76 The ability of tumor-infiltrating immune cells to promote tumor growth

77 ntifies the proportions of stromal cells and tumor-infiltrating immune cells, as well as associations

78 Tumor-infiltrating immune cells, especially CD3(+) T cel

79 Among tumor-infiltrating immune cells, tumor-associated macrop

80 clusters in a scRNAseq experiment involving tumor-infiltrating immune cells.

81 omising solution to rapidly characterize the tumor-infiltrating immune landscape and identify cold ca

82 (2019) demonstrate a novel role for tumor-infiltrating innate-like B1a B cells in promoting

83 c on malignant cells increased the number of tumor-infiltrating interferon gamma-producing natural ki

84 local p53 activation in TME comprising overt tumor-infiltrating leukocytes (TILeus) induces systemic

85 pression deconvolution approach for studying tumor-infiltrating leukocytes (TILs) in 23 cancer types

86 cancers with high levels of CCR4-expressing tumor-infiltrating leukocytes and abnormal plasma CCR4 l

87 CC that manipulates the activation status of tumor-infiltrating leukocytes and renders them immunocom

88 phocyte antigen-4 (CTLA-4), respectively, on tumor-infiltrating leukocytes eliciting immunosuppressio

89 ow cytometric analysis showed alterations in tumor-infiltrating leukocytes in the absence of C3aR.

90 Analysis of tumor-infiltrating leukocytes revealed significant reduc

91 facilitated the targeted gene expression in tumor-infiltrating leukocytes, including antigen-present

92 6-mediated TGI was associated with increased tumor-infiltrating leukocytes, M1-polarized intratumoral

93 eneic tumor cells showed >80% GFP marking in tumor-infiltrating leukocytes.

94 noma model, the frequency of PD-1-expressing tumor-infiltrating LSD1-deficient CD8 T cells was greate

95 or without 1,200 cGy TBI before transfer of tumor-infiltrating lymphcytes.

96 ed stage melanoma patients undergoing either tumor infiltrating lymphocyte (TIL)-based or anti- progr

97 ltration, cytolytic activity, and abundance (tumor infiltrating lymphocyte, TIL, burden).

98 Reduction of CCL5 expression caused tumor-infiltrating lymphocyte (TIL) desertification, whe

99 Finally, we evaluated the immune cell tumor-infiltrating lymphocyte (TIL) score for correlatio

100 checkpoint blockade and adoptive transfer of tumor-infiltrating lymphocyte (TIL)-based therapies.

101 eventing dendritic cell (DC)-mediated CD8(+) tumor-infiltrating lymphocyte apoptosis through regulati

102 g lymphocytes in a subset of TNBCs with high tumor-infiltrating lymphocyte content.

103 with RNA-seq, MHCII protein expression, and tumor-infiltrating lymphocyte counts.

104 Tumor-infiltrating lymphocyte estimated using immune cel

105 We also mined a tumor-infiltrating lymphocyte sample from a patient with

106 his investigation, we explored the effect of tumor-infiltrating lymphocyte subpopulations on lung can

107 hin DNA; making them more prone to attack by tumor infiltrating lymphocytes (TIL) and macrophages.

108 stimulatory microenvironment harboring more tumor infiltrating lymphocytes (TILs) and up-regulation

109 Assessment of tumor infiltrating lymphocytes (TILs) as a prognostic va

110 (RT) on the basis of the presence of stromal tumor infiltrating lymphocytes (TILs) have not been stud

111 We find a higher response of patient-matched tumor infiltrating lymphocytes against antigens diferent

112 lerated, inhibits RANK pathway and increases tumor infiltrating lymphocytes and CD8(+) T cells.

113 own that MHC class II (MHCII) expression and tumor infiltrating lymphocytes are important prognostic

114 Rationale Tumor infiltrating lymphocytes are widely associated wit

115 fy gene signatures common to circulating and tumor infiltrating lymphocytes in the context of clear c

116 nd inversely correlated with the presence of tumor infiltrating lymphocytes indicating that HS-27 flu

117 the prognostic significance of intratumoral tumor infiltrating lymphocytes, as well as subsets of CD

118 Such T cells can be detected in tumor infiltrating lymphocytes, but whether such cells c

119 ere recorded and associated with presence of tumor infiltrating lymphocytes, cyclin E, adipophilin, p

120 rates, independent of increased pretreatment tumor infiltrating lymphocytes.

121 s barriers to the metabolism and activity of tumor infiltrating lymphocytes.

122 Direct competition between tumor-infiltrating lymphocytes (TIL) and cancer cells fo

123 We isolated tumor-infiltrating lymphocytes (TIL) and intra-hepatic l

124 A, and CD4 mRNAs and their relationship with tumor-infiltrating lymphocytes (TIL) and PD-L1 IHC expre

125 Tumor-infiltrating lymphocytes (TIL) are potent mediator

126 Recent studies have found that tumor-infiltrating lymphocytes (TIL) expressing PD-1 can

127 Here, we show that P2X7 activity in tumor-infiltrating lymphocytes (TIL) induces cellular se

128 The presence of tumor-infiltrating lymphocytes (TIL) is a favorable prog

129 sment of spatial relations between tumor and tumor-infiltrating lymphocytes (TIL) is increasingly imp

130 sms of self-tolerance often result in CD8(+) tumor-infiltrating lymphocytes (TIL) with a hypofunction

131 agent DAC led to increased CD4(+) and CD8(+) tumor-infiltrating lymphocytes (TIL), PD1 expression, an

132 d minimal toxicity in ex vivo-expanded human tumor-infiltrating lymphocytes (TIL), proliferating TILs

133 dynamics of the effector response of CD8(+) tumor-infiltrating lymphocytes (TILs) after checkpoint b

134 antigen-specific, activated effector CD8(+) tumor-infiltrating lymphocytes (TILs) after interaction

135 xamined the role of CD226 in the function of tumor-infiltrating lymphocytes (TILs) and resistance to

136 Tumor-infiltrating lymphocytes (TILs) are an important h

137 Accumulating evidence indicates that tumor-infiltrating lymphocytes (TILs) are associated wit

138 It is well known that CD8(+) tumor-infiltrating lymphocytes (TILs) are correlated wit

139 umors; however, the antigen specificities of tumor-infiltrating lymphocytes (TILs) are not well under

140 rapy (ACT) using ex vivo-expanded autologous tumor-infiltrating lymphocytes (TILs) can mediate comple

141 sis survivors had a reduced frequency of CD8 tumor-infiltrating lymphocytes (TILs) concomitant with a

142 c Abs enhances the expansion and function of tumor-infiltrating lymphocytes (TILs) for treating cance

143 tified a unique ILC population that inhibits tumor-infiltrating lymphocytes (TILs) from high-grade se

144 Tregs represented a large proportion of the tumor-infiltrating lymphocytes (TILs) in claudin-low tum

145 at have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage tri

146 Although the presence of tumor-infiltrating lymphocytes (TILs) indicates an endog

147 Importance: The presence of tumor-infiltrating lymphocytes (TILs) is a favorable pro

148 n of T cell clones by limiting dilution from tumor-infiltrating lymphocytes (TILs) permitted function

149 However, the evaluation of tumor-infiltrating lymphocytes (TILs) relies on histopat

150 ession and chromatin accessibility in CD8(+) tumor-infiltrating lymphocytes (TILs) that recognize a m

151 s by reactivating a population of endogenous tumor-infiltrating lymphocytes (TILs) that recognize can

152 FS), multifunctionality of CD8 + splenic and tumor-infiltrating lymphocytes (TILs) was impaired and a

153 Percentage of tumor cells and tumor-infiltrating lymphocytes (TILs) with PD-L1 express

154 The distribution of tumor-infiltrating lymphocytes (TILs) within the tumor m

155 ent survival, an immune response linked with tumor-infiltrating lymphocytes (TILs), and a repressed C

156 infiltrating immune cells (IC), abundance of tumor-infiltrating lymphocytes (TILs), and expression of

157 ells share core residency gene programs with tumor-infiltrating lymphocytes (TILs).

158 a specific subpopulation of exhausted CD8(+) tumor-infiltrating lymphocytes (TILs).

159 ive T cell therapy (ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs).

160 signaling from naive to dysfunctional CD8(+) tumor-infiltrating lymphocytes (TILs).

161 modulating inhibitory receptor expression on tumor-infiltrating lymphocytes (TILs); however, the unde

162 Intraepithelial/stromal tumor-infiltrating lymphocytes (TILs; CD3(+)/CD4(+)/CD8(

163 ing of freshly isolated CD8(+)/CD103(+) lung tumor-infiltrating lymphocytes and CD103(+) tumor-specif

164 s corresponded with significant increases in tumor-infiltrating lymphocytes and increased expression

165 condary endpoints included the generation of tumor-infiltrating lymphocytes and modulation of immune

166 heckpoint inhibitors increases the number of tumor-infiltrating lymphocytes and overall survival afte

167 Tumor-infiltrating lymphocytes appear to be a predictor

168 A paradox of tumor immunology is that tumor-infiltrating lymphocytes are dysfunctional in situ

169 ound that the presence and quantification of tumor-infiltrating lymphocytes are significantly associa

170 Generation of tumor-infiltrating lymphocytes begins when tumor antigen

171 l expression in thousands of tumor cells and tumor-infiltrating lymphocytes can be used to obtain a s

172 Tumor-infiltrating lymphocytes coexpressed PD-1 with the

173 tion, FACS-based enumeration of intracranial tumor-infiltrating lymphocytes directly correlated with

174 CD8(+) tumor-infiltrating lymphocytes displayed low expression

175 In the presence of Wnt5A-depleted MDSC, tumor-infiltrating lymphocytes expressed decreased PD-1

176 biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resect

177 CD8(+) tumor-infiltrating lymphocytes harboring ubiquitous TCRs

178 rong SFK_pY416 staining was also observed in tumor-infiltrating lymphocytes in a subset of TNBCs with

179 utility of this tool by using it to classify tumor-infiltrating lymphocytes in breast carcinoma and c

180 Patients with increased numbers of tumor-infiltrating lymphocytes in primary colon tumors a

181 Approaches to enhance tumor-infiltrating lymphocytes in the tumor bed may subs

182 ssociated with significantly lower levels of tumor-infiltrating lymphocytes in triple-negative breast

183 The presence of tumor-infiltrating lymphocytes in triple-negative breast

184 Systematic interrogation of tumor-infiltrating lymphocytes is key to the development

185 s also found in the draining lymph nodes and tumor-infiltrating lymphocytes of OSCC patients with ear

186 Moreover, CCR6(+) Treg cells isolated from tumor-infiltrating lymphocytes or draining lymph nodes m

187 ade relies on reinvigoration of pre-existing tumor-infiltrating lymphocytes or on recruitment of nove

188 Examination of tumor-infiltrating lymphocytes revealed an elevated popu

189 Tumor-infiltrating lymphocytes showed a prevalent inhibi

190 -1:28 engineering reinstated Th1 function in tumor-infiltrating lymphocytes that had been functionall

191 ls of chemotherapy or radiation can increase tumor-infiltrating lymphocytes that overcome resistance

192 oximately 1.11x10(11) HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of fou

193 METHODSWe recently developed a process using tumor-infiltrating lymphocytes to identify the specific

194 le MEK inhibition can promote recruitment of tumor-infiltrating lymphocytes to the tumor, here we sho

195 The number of tumor-infiltrating lymphocytes was also reduced in LKB1-

196 lls and enhancement of antitumor activity in tumor-infiltrating lymphocytes without disrupting immune

197 zed that rapidly proliferating cancer cells, tumor-infiltrating lymphocytes, and vascular endothelial

198 ressor gene, Ki-67 proliferation marker, and tumor-infiltrating lymphocytes, carry prognostic signifi

199 ave PD-L1 expression in both tumor cells and tumor-infiltrating lymphocytes, suggesting that immune c

200 -eosin and immunohistochemical stainings for tumor-infiltrating lymphocytes, tissue-based hypoxia, an

201 h model, GSK-3i inhibited PD-1 expression on tumor-infiltrating lymphocytes, while increasing Tbx21 (

202 tualized as resulting from reinvigoration of tumor-infiltrating lymphocytes.

203 mune cell scores and histologically detected tumor-infiltrating lymphocytes.

204 ith expression preceding the infiltration of tumor-infiltrating lymphocytes.

205 or growth was measured by serial ultrasound, tumor-infiltrating lymphoid and myeloid cells were chara

206 hem from mature lymphatic endothelial cells, tumor-infiltrating lymphoid cells, and tissue-resident m

207 owth and increases both TILs and a subset of tumor-infiltrating M2-polarized macrophages in the KPC m

208 (Ym1), reflecting an increase in a subset of tumor-infiltrating M2-polarized macrophages.

209 ng the innate immune response and increasing tumor infiltrating macrophages.

210 Finally, NLRP3 expression in tumor-infiltrating macrophages correlated with survival,

211 Additionally, tumor-infiltrating macrophages from sh-a2 tumors showed

212 gene signature and CD274 gene expression in tumor-infiltrating macrophages in humans.

213 y found that obesity leads to an increase in tumor-infiltrating macrophages with activated NLRC4 infl

214 TREM2 is also expressed by tumor-infiltrating macrophages.

215 Tumor-infiltrating MDSC from control animals showed a st

216 there are a large number of circulating and tumor-infiltrating MDSCs existing in gastric cancer (GC)

217 In addition, our investigation showed that tumor-infiltrating MDSCs from 6 GAC patients consisted o

218 al confounding effects of gene expression by tumor-infiltrating mesenchymal stromal cells.

219 on of several derepressed miR-155 targets in tumor-infiltrating, miR-155-deficient CD8(+) T cells, su

220 both pro- and anti-inflammatory pathways in tumor infiltrating monocytes.

221 on profile of blood-derived monocytes versus tumor-infiltrating monocytes and found increased express

222 ssion, evaluated by immunohistochemistry, on tumor infiltrating mononuclear cells (TIMCs) and tumor c

223 sion was recently found to be upregulated on tumor-infiltrating murine (CD11c(+)CD11b(+)CD8(-)CD209a(

224 essed on and thereby impair the functions of tumor-infiltrating murine and human myeloid dendritic ce

225 ic and phenotypic profile resembling that of tumor infiltrating myeloid and lymphoid populations, but

226 h the complement C5a receptor 1 expressed on tumor infiltrating myeloid-derived suppressor cells.

227 Moreover, we identified changes in tumor-infiltrating myeloid cell (TIM) subsets that likel

228 Tumor-infiltrating myeloid cells (TIMs) comprise monocyt

229 ved in the regulation of PD-L1 expression in tumor-infiltrating myeloid cells and, therefore, reprogr

230 d that local nitric oxide (NO) production by tumor-infiltrating myeloid cells is important for adopti

231 roadly upregulated on human cancer cells and tumor-infiltrating myeloid cells, and its expression is

232 what is currently known about the origin of tumor-infiltrating nerves, how they may be recruited to

233 We demonstrated in a recent study that tumor-infiltrating neutrophil density correlated with TC

234 of potent antigen-presenting cells, such as tumor-infiltrating neutrophils and activated dendritic c

235 Tumor-infiltrating neutrophils have been implicated in m

236 NKp30 targeting versus CD56 for detection of tumor infiltrating NK cells.

237 trating the expression of these receptors on tumor-infiltrating NK cells in human tumors, whereas tum

238 ing signals to achieve in situ activation of tumor-infiltrating NK cells, as well as direction of the

239 NKp30, and NKp46 to determine expression on tumor-infiltrating NK cells.

240 Finally, we find that tumor infiltrating NKT cells are highly enriched for the

241 ed DNA-methylation programs were acquired in tumor-infiltrating PD-1hi CD8 T cells, and approaches to

242 Tumor-infiltrating PD-L1(+) cells isolated from tumor-be

243 vivo associated with decreased frequency of tumor-infiltrating PD-L1(+)CD11b(+)Gr1(+) MDSC.

244 ted macrophages, but also an accumulation of tumor-infiltrating polymorphonuclear mononuclear cells c

245 r by remotely supplying a distinct subset of tumor-infiltrating SiglecF(high) neutrophils, which exhi

246 ave uncovered a significant heterogeneity of tumor-infiltrating slan(+) -cells, including a macrophag

247 Tumor-infiltrating stromal cells, which include macropha

248 mice led to the downregulation of CTLA-4 on tumor -infiltrating T cells, which was associated with t

249 -gamma and TNF-alpha released from activated tumor infiltrating T cells is likely responsible for the

250 ve microenvironment, significantly increased tumor infiltrating T cells, lowered the hypoxia level, d

251 These analyses reveal a spectrum of tumor-infiltrating T cell populations that are highly si

252 nt blockade targets only specific subsets of tumor-infiltrating T cell populations.

253 There were more tumor-infiltrating T cells and MHCII(hi)-immune cells in

254 cal promise in a variety of cancers, but how tumor-infiltrating T cells are activated remains unclear

255 uppress the expression of CTLA-4 molecule on tumor-infiltrating T cells by siRNA-loaded chitosan-lact

256 In this study, we tested the hypothesis that tumor-infiltrating T cells could be more effectively act

257 The majority of tumor-infiltrating T cells exhibit a terminally exhauste

258 Gene expression analyses of tumor-infiltrating T cells following Yap deletion implic

259 established tumors promotes re-activation of tumor-infiltrating T cells for tumor control.

260 ncreased the persistence and accumulation of tumor-infiltrating T cells in vivo, compared with the pa

261 The presence of tumor-infiltrating T cells is associated with favorable

262 Tumor-infiltrating T cells mainly displayed exhausted an

263 r reprogramming of the altered metabolism of tumor-infiltrating T cells might represent a potential s

264 Tumor-infiltrating T cells play an important role in man

265 Dysregulation of this pathway in tumor-infiltrating T cells results in diminished anti-tu

266 Tumor-infiltrating T cells showed a progressive loss of

267 Sepsis-resistant CD8 tumor-infiltrating T cells showed increased in vivo acti

268 Sepsis-reinvigorated CD8 tumor-infiltrating T cells were also amenable to (anti-P

269 Presence of tumor-infiltrating T cells, but not programmed death-lig

270 oenvironment, including increased numbers of tumor-infiltrating T cells, elevated IFN signaling, and

271 -colonizing bacteria increases activation of tumor-infiltrating T cells, stimulates rapid tumor regre

272 tant to immune checkpoint therapy due to few tumor-infiltrating T cells.

273 hin a FL and examined the characteristics of tumor-infiltrating T cells.

274 d decreases MLK3 and Ppia gene expression in tumor-infiltrating T cells.

275 tumor growth by suppressing the activity of tumor-infiltrating T cells.

276 allel with an ipilimumab-induced increase in tumor-infiltrating T cells.

277 ts with DCB displayed a higher proportion of tumor-infiltrating T lymphocytes (TIL) (n = 24, Mann-Whi

278 ht to understand the molecular correlates of tumor-infiltrating T lymphocytes (TIL) in squamous cell

279 by similar means as those used to reactivate tumor-infiltrating T lymphocytes (TIL), for example, by

280 enhances the proliferation of both naive and tumor-infiltrating T lymphocytes (TIL).

281 How tumor-infiltrating T lymphocytes (TILs) adapt to the met

282 pped shared antigenic epitopes recognized by tumor-infiltrating T lymphocytes (TILs) from eight melan

283 metabolic fitness and antitumor activity of tumor-infiltrating T lymphocytes (TILs).

284 blockade increases IFNgamma-producing CD8(+) tumor-infiltrating T lymphocytes and results in a profou

285 ory immune checkpoint molecules expressed on tumor-infiltrating T lymphocytes, such as cytotoxic T-ly

286 ion and augmented TCR clonal diversity among tumor-infiltrating T lymphocytes, supporting a local imm

287 to off-target suppression of the activity of tumor-infiltrating T lymphocytes.

288 cell clones did not derive from pre-existing tumor-infiltrating T lymphocytes; instead, the expanded

289 eckpoint molecules PDL1 and CTLA4, increased tumor-infiltrating T regulatory cells, and decreased nat

290 nd CDK4/6 inhibition significantly increased tumor-infiltrating T-cell activation and cytotoxicity an

291 tumors, concurrent with an increase in CD8 + tumor-infiltrating T-cells expressing granzyme B and int

292 Results: High levels of tumor-infiltrating total lymphocytes correlated with sup

293 umor microenvironment and the composition of tumor-infiltrating Treg and myeloid-derived suppressor c

294 hat CD25 expression is largely restricted to tumor-infiltrating Treg cells in mice and humans.

295 ting FcgammaRs led to effective depletion of tumor-infiltrating Treg cells, increased effector to Tre

296 e, MK-4166 downregulated FOXP3 mRNA in human tumor infiltrating Tregs, suggesting that, in addition t

297 duced potent antitumor effects by decreasing tumor-infiltrating Tregs and increasing the infiltration

298 TR was comparable with that of mouse GITR in tumor-infiltrating Tregs despite being drastically lower

299 immune molecules preferentially expressed on tumor-infiltrating Tregs.

300 Tumor-infiltrating Trx1+ NK cells were present in patien